Klick Health

GSK and Merck use social media for in market insights

Editor

in
Read More

GSK and Merck are using a social scanning tool called Epidemico to gather social insights after being anonymized. This process allows the companies to use the data without worrying about which posts need to be reported as adverse events to the FDA.

“To put that in perspective, there’s more adverse events discussions online, in social media, in one year than there are in the FDA database since it started in 1968,” [Greg Powell, director of pharmacovigilance at GlaxoSmithKline] said.

GSK was looking at what patients were saying about its drugs, to the tune of 6 million posts on Twitter and 15 million on Facebook, and Merck was working with PatientsLikeMe to study how potential patents for a new drug were speaking about their condition.

What Merck found by examining data from the 90,000 insomnia patients on PatientsLikeMe was that even patients who tell their doctor they’re satisfied with their sleep medication are often continuing to have sleep problems.

Other stories from MobiHealthNews:

Source: MobiHealthNews

More About the Author

Klick Wire

This is the Klick Wire blog account. Here you will find archived versions of all your favorite Klick Wire stories. To get these stories delivered to your inbox every week, use the sign up form at the bottom of this page.

More from this author

Go from news to action. Klick Wire

Weekly Digital Health Newsletter

Klick Health will NEVER spam you. Read our privacy policy

Thank you! You're now signed up to get the Klick Wire every week - news from the world of digital health marketing.

Sorry there seems to be a problem. Please try again later.